1. Opening Hook
While most pharma CEOs are busy explaining why margins “temporarily dipped,” Caplin Point’s Chairman opened the concall with Steven Pinker, empathy, robots, and the bottom of the pyramid. Naturally.
In a world obsessed with biosimilars, Caplin is still selling penicillin to rural Latin America—and somehow printing cash doing it. Q2 numbers came in steady, H1 profits quietly crossed FY22 full-year PAT, and management sounded almost bored by success.
No panic on tariffs. No debt drama. No Excel gymnastics. Just a lot of talk about warehouses, injectables, China trips, and why private markets beat tenders every single time.
Stick around—because behind the philosophical rambling lies a company sitting on ₹2,358 crore of liquid assets, plotting Mexico, Guatemala, oncology injectables, and maybe a $300 million acquisition… someday. 😏
Read on. It only gets more interesting once the sarcasm fades and the cash flow shows up.
2. At a Glance
- Revenue up 11% YoY – Boring growth, but on a base that already embarrasses peers.
- EBITDA up 18% – Profits growing faster than sales; finance teams elsewhere crying softly.
- PAT margin at 28.3% – Management promised 25%, casually delivered more.
- Cash & liquid assets ₹2,358 crore – Enough dry powder to buy ambition wholesale.
- Zero debt – Interest expense still missing, presumed kidnapped.
- US front-end profitable in 9 months – Breakeven targets officially humiliated.
3. Management’s Key Commentary
“Private knowledge alone can create competitive advantage.”
(Translation: Our model is weird, hard to copy, and very profitable.) 😏
“We are not competing with big pharma; we are creating a new ecosystem.”
(Translation: They fight tenders. We own warehouses.)
“Liquid assets exceed annual revenue.”
(Translation: We’re allergic to leverage and sleep very well.)
“We will be among the top 4–5 injectable exporters to the US.”
(Translation: Scale incoming, price erosion be damned.)
“CSU broke even in the first quarter itself.”
(Translation: Our US experiment worked faster than planned.)
“We rejected a $300 million acquisition opportunity.”
(Translation: Not desperate, just picky.) 😌
“Top line is quantity; bottom line is sanity.”
(Translation: Growth without cash is a personality disorder.)
4. Numbers Decoded
Metric Q2 / H1 FY26 Snapshot
---------------------------------------------------------
Revenue Growth +11% YoY
EBITDA
